Zeichner JA. Update on Isotretinoin, Depression, and Suicide: Appropriate Monitoring is Key. Practical Dermatology.
2011 Jan; 8 (1): 32-34.
Zeichner JA and Cohen JL. Dermal fillers in patients on anticoagulants. J Drugs Dermatol. 2010 Sep;9(9):1059-60.
Frankel AJ, Zeichner JA, Del Rosso JQ. Coal Tar 2% Foam in Combination with a Superpotent Corticosteroid Foam for Plaque
Psoriasis. J Clin Aesth Dermatol. 2010; 3(10): 42-45.
Zeichner JA. Use of Topical Coal Tar Foam for the Treatment of Psoriasis in Difficult-to-treat Areas. J Clin Aesthet Dermatol.
2010; 3(9): 37–40.
Zeichner JA, Lebwohl MG, Menter A, et al. Optimizing Topical Therapies for Treating Psoriasis: A Consensus Conference.
Cutis. 2010; 86(3S): 1-32.
Fernandes NF and Zeichner JA. Laser and Light-based treatments for acne vulgaris. Cosmetic Dermatology. 2010; 23(8):
Emer, J and Zeichner, JA. A Practical Approach to Monitoring Patients on Biological Agents for the Treatment of Psoriasis. J
Clin Aesthetic Dermatol. 2010; 3(8): 20–26.
Kling M, Zeichner JA. HPV vaccination in the developing world. J Int Dermatol. 2010;49:377-379.
Zeichner JA, Stern DWK, Uliasz A, et al. “Placebo-controlled, double blind, randomized study of imiquimod 5% cream applied
once per week for six months for the treatment of actinic keratoses.” J Am Acad of Dermatol. 2009. 60 (1): 59-62.
Breneman D, Fleischer AB Jr, Abramovits W, Zeichner J, et al. “Intermittent therapy for flare prevention and long-term
disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus
ointment versus vehicle.” J Am Acad Dermatol. 2008 Jun; 58 (6): 990-9.
Zeichner, JA. “A Practical Approach to Screening Psoriasis Patients for Therapy with Biologic Agents.” J Clin Aesth Dermatol. 1
2008; 1 (3): 50-54.
Saggar S, Zeichner JA, Brown TT, et al. “Kaposi's sarcoma resolves after sirolimus therapy in a patient with pemphigus
vulgaris.” Arch Dermatol. 2008 May; 144 (5): 654-7.
Boguniewicz M, Zeichner JA, Eichenfield LF, et al. “MAS063DP is effective monotherapy for mild to moderate atopic dermatitis
in infants and children: a multicenter, randomized, vehicle-controlled study.” J Pediatr. 2008; 152 (6): 854-9.
Uliasz A, Zeichner J, Soung J, et al. “A Single-Center, Double-Blind, Randomized Trial of the Atrophogenic Effects of
Fluocinonide Cream 0.1% Versus Clobetasol Propionate Cream 0.05% in Participants With Corticosteroid-Responsive
Dermatoses.” Cutis. 2008; 81: 517-519.
Zeichner, JA and Sadick N. “A History of Lasers in Dermatologic Surgery.” Am J Cosm Surg. Vol 25, No 4, 2008.
Zeichner JA and Lebwohl M. “Potential Complications Associated with the Use of Biologic Agents.” Dermatol Clin. 2007 Apr;25
Chinn S and Zeichner JA. “The Direct Correlation Between Total Body Surface Area Involvement and PASI Scores in Judging
Psoriasis Severity.” Psoriasis Forum. Winter 2007; 13(2): 13-15.
Hodulik SG and Zeichner JA. “Combination therapy with acitretin for psoriasis.” J Dermatolog Treat. 2006; 17(2):108-11.
Halverstam C, Zeichner JA, Lebwohl M. “Lack of significant skeletal changes after long-term low-dose retinoid therapy: a
case report and review of the literature.” J Cut Med Surg. 2006 Nov-Dec; 10(6):291-9.
Zeichner JA, Stern DW, Lebwohl M. “Treatment of necrobiosis lipoidica with the tumor necrosis factor antagonist etanercept.”
J Am Acad Dermatol. 2006 Mar; 54 (3 Suppl 2):S120-1.
Chu J and Zeichner JA. “Vaccination of patients on Biologic Agents for Psoriasis.” Psoriasis Forum. Fall 2005. Vol 11, No 3:
Ignat F and Zeichner J. “Financial limitations in treating vitiligo.” Vitiligo Bulletin. 2004. Vol 9, No 7: p. 1.
Muigai W and Zeichner J. “Psoriatic and Rheumatoid Arthritis: Distinguishing Characteristics.” Psoriasis Forum. Fall 2004. Vol
10, No 3: pp. 4-5.
Zeichner J, Behnan S, Smith DR, et al. “Etanercept: Questions and Answers.” Psoriasis Forum. Summer 2004. Vol 10, No 2:
Saavedra WF, Paolocci N, St John ME, Skaf MW, Stewart GC, Xie JS, Harrison RW, Zeichner J, et al. “Imbalance between
xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart.”
Circulation Research. February 22, 2002; 90 (3): pp. 297-304.
Zeichner J and Dalton J. “Chapter 190: Radiation Dermatitis.” Treatment of Skin Disease: Comprehensive Therapeutic
Strategies. 2nd Edition. Lebwohl M, Heymann W, Berth-Jones J, et al. Elsevier Science. 2004.
POSTERS AND PRESENTAIONS
Abramovits W, Breneman D, Fleischer A, Zeichner J, Shull T. “Utility in Flare Prevention and Maintenance Therapy of Long-
Term Intermittent Treatment With Tacrolimus Ointment in Patients With Atopic Dermatitis.” DNA 2009 conference, March 4-7,
2009. San Francisco.
Fuchs A, Zeichner J, and Lebwohl M. “Squamous Cell Carcinoma arising in area of long-standing Necrobiosis Lipoidica: A case
report and review of literature.” Summer American Academy of Dermatology Meeting. Chicago, IL July 2008.
Boginiewcz M, Zeichner JA, Eichenfeld LF, et al. “A Multicenter, Double-Blind, Vehicle-Controlled Clinical Study to Evaluate the
Efficacy and Tolerability of MAS063DP (Atopiclair/Zarzenda) in the Management of Mild to Moderate Atopic Dermatitis in
Children and Infants.” World Congress Meeting. Buenos Aires, Argentina. September 2007.
Breneman D, Fleischer AB, Abramovits W, Zeichner J. “Long-Term Intermittent Treatment with Tacrolimus Ointment is Useful
in Flare Prevention & Maintenance Therapy of Atopic Dermatitis.” Summer American Academy of Dermatology Meeting. New
York. August 2007.
Zeichner JA, Stern D, Uliasz A, et al. “Once weekly application of imiquimod 5% cream for the treatment of actinic
keratoses.” Presented at the Annual American Academy of Dermatology Meeting. Washington, DC. February 2-6, 2007.
Breneman D, Zeichner J, Abramovits W. “Tacrolimus ointment applied three times weekly as non-continuous chronic
management of moderate to severe atopic dermatitis.” Presented at the Annual American Academy of Dermatology
Meeting. Washington, DC. February 2-6, 2007.
Zeichner JA, Blum R, Lebwohl M, and Cohen SR. “Results of a Phase I, Single-center, Open-label Study to Assess the Safety
and Evaluate the Activity of Rituximab for the Treatment of Pemphigus Vulgaris.” Presented at the Fall Clinical Dermatology
Meeting. MGM Grand Hotel. Las Vegas, NV. October 6-9, 2006.
Erianne J, Ramirez J, Wilson D, Zeichner J. “The Pharmacologic Science of A Novel Benzoyl Peroxide Formulation and the
Implications for Clinical Effects.”OMP Pharmaceuticals. Presented at the Fall Clinical Dermatology Meeting. MGM Grand Hotel.
Las Vegas, NV. October 6-9, 2006.
Zeichner JA and Lebwohl M. “An assessment of the safety and efficacy of cryosurgery alone compared with sequential
treatment with diclofenac sodium gel 3% after cryosurgery for the treatment of actinic keratoses.” Presented at the Summer
American Academy of Dermatology Meeting. San Diego, CA. July 26-30, 2006.
Goldberg DJ, Zeichner JA, Hodulik SG, Marmur E. Q-switched Laser Irradiation of Pigmented Nevi: Analysis of Markers for
Malignant Transformation. American Society for Laser Medicine and Surgery, Twenty-Sixth Annual Meeting, Boston,
Massachusetts, April 5-April 9, 2006.
Halverstam CP, Zeichner JA, and Lebwohl M. “Lack of significant skeletal changes associated with long-term, low-dose
acitretin therapy.” Presented at the Annual Academy of Dermatology Meeting. The Moscone Center. San Francisco, CA . March
Blum RR, Singer GK, Stern DK, et al. “Oral phosphate binders in the treatment of pseudoxanthoma elasticum.” Presented at
the Annual Academy of Dermatology Meeting. The Moscone Center. San Francisco, CA . March 3-7, 2006.
Hanifin JM, Tyring S, Zeichner J, et al. “A novel topical NF-κB Decoy: Results from a Phase 1/2 trial in atopic dermatitis.”
Presented at the Annual Academy of Dermatology Meeting. The Moscone Center. San Francisco, CA . March 3-7, 2006.
Zeichner J, Stern D, Lebwohl M. “Intralesional etanercept for the treatment of necrobiosis lipoidica.” Poster presented at the
Atlantic Dermatology Meeting. Grand Hyatt Hotel. New York, NY. May 20-22, 2005. Zeichner J, Lebwohl M.
Zeichner JA and Lebwohl M. “Pilot investigation of topical tacrolimus 0.1% ointment in combination with topical hydrocortisone
butyrate 0.1% lipocream in the treatment of atopic dermatitis of the face and intertriginous areas versus the trunk and
extremities.” Poster presented at the American Academy of Dermatology Annual Winter Meeting. New Orleans, LA. February